Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Essential Hypertension: later-stage trial registry
1 of 9 indexed Essential Hypertension trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 1 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Essential Hypertension: 9 US clinical trials tracked, 1 recruiting.
Essential Hypertension is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis, running 3 of these trials.
Enrollment posture brief
Registry condition essential-hypertension
OPEN 1 | RECR 11% | LATE 4 | EARLY 2 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Alcohol Use Disorders (11% recruiting · 9 trials)
Essential Hypertension lists 1 open slots (11% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Essential Hypertension on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Essential Hypertension is recruiting below its size-band peers.
1 of 9 indexed trials (11.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Essential Hypertension research.
Novartis accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Essential Hypertension enrolment sits around 564 participants.
Median target enrolment is 564 among the 9 trials that report a genuine target (sentinel values excluded). 3 of those (33.3%) plan for fewer than 100 participants.
-
Essential Hypertension research is mostly interventional.
7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Childhood-Onset Essential Hypertension Natural History Study
National Human Genome Research Institute (NHGRI)
NCT06778239
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
Novartis
NCT06604897
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
Takeda
NCT00846365
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
Takeda
NCT00818883
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
Novartis
NCT00667719
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
Novartis
NCT00654875
Hypertension: Prediction of Biofeedback Success
National Center for Complementary and Integrative Health (NCCIH)
NCT00026065
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
Roxane Laboratories
NCT01012687
Uric Acid in Essential Hypertension in Children
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00288184
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Essential Hypertension records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Essential Hypertension trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Essential Hypertension page
9 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Essential Hypertension trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis sponsors the most Essential Hypertension trials on record, review their full trial history before evaluating a specific study. See Novartis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Essential Hypertension condition card totals 9 registered trials; most-linked intervention Azilsartan medoxomil and chlorthalidone; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.